uniQure (NASDAQ:QURE) Stock Holdings Increased by Swiss National Bank

Swiss National Bank boosted its position in uniQure (NASDAQ:QURE – Get Rating) by 1.9% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 101,500 shares of the biotechnology company’s stock after buying an additional 1,900 shares during the quarter. Swiss National Bank owned approximately 0.22% of uniQure worth $2,301,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors also recently bought and sold shares of the stock. BlackRock Inc. boosted its stake in uniQure by 14.0% in the third quarter. BlackRock Inc. now owns 4,898,640 shares of the biotechnology company’s stock valued at $91,897,000 after acquiring an additional 599,805 shares during the period. Point72 Asset Management L.P. boosted its stake in uniQure by 11.5% in the third quarter. Point72 Asset Management L.P. now owns 4,259,886 shares of the biotechnology company’s stock valued at $79,915,000 after acquiring an additional 440,186 shares during the period. State Street Corp boosted its stake in uniQure by 29.5% in the third quarter. State Street Corp now owns 3,063,265 shares of the biotechnology company’s stock valued at $57,467,000 after acquiring an additional 698,121 shares during the period. PFM Health Sciences LP boosted its stake in uniQure by 7.0% in the third quarter. PFM Health Sciences LP now owns 2,393,311 shares of the biotechnology company’s stock valued at $44,899,000 after acquiring an additional 156,941 shares during the period. Finally, Vanguard Group Inc. boosted its stake in uniQure by 10.9% in the third quarter. Vanguard Group Inc. now owns 1,434,004 shares of the biotechnology company’s stock valued at $26,903,000 after acquiring an additional 141,382 shares during the period. 88.03% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

QURE has been the subject of a number of research reports. HC Wainwright restated a “buy” rating and issued a $90.00 target price on shares of uniQure in a research note on Tuesday, March 7th. 1-800-FLOWERS.COM reiterated a “maintains” rating on shares of uniQure in a research report on Tuesday, May 16th. Truist Financial reduced their price objective on uniQure from $65.00 to $55.00 in a research report on Thursday, May 11th. Guggenheim reiterated a “buy” rating and set a $53.00 price objective on shares of uniQure in a research report on Tuesday, February 28th. Finally, Credit Suisse Group boosted their price objective on uniQure from $51.00 to $55.00 and gave the stock an “outperform” rating in a research report on Tuesday, February 28th. Two equities research analysts have rated the stock with a hold rating and seven have issued a buy rating to the company. According to MarketBeat, uniQure presently has an average rating of “Moderate Buy” and a consensus target price of $54.00.

Insider Activity

In other news, CEO Matthew C. Kapusta sold 2,521 shares of the stock in a transaction on Tuesday, March 7th. The stock was sold at an average price of $21.39, for a total transaction of $53,924.19. Following the completion of the sale, the chief executive officer now owns 468,743 shares in the company, valued at approximately $10,026,412.77. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. In the last 90 days, insiders sold 5,919 shares of company stock worth $126,208. Insiders own 3.10% of the company’s stock.

uniQure Stock Performance

Shares of NASDAQ QURE opened at $20.40 on Thursday. The stock has a fifty day moving average price of $20.07 and a two-hundred day moving average price of $21.44. The company has a debt-to-equity ratio of 0.25, a quick ratio of 6.56 and a current ratio of 6.67. The firm has a market cap of $970.63 million, a P/E ratio of -6.15 and a beta of 1.18. uniQure has a 1 year low of $12.98 and a 1 year high of $28.25.

uniQure (NASDAQ:QURE – Get Rating) last announced its quarterly earnings data on Monday, February 27th. The biotechnology company reported $0.15 EPS for the quarter, beating analysts’ consensus estimates of ($0.89) by $1.04. uniQure had a negative return on equity of 35.03% and a negative net margin of 143.01%. The company had revenue of $102.75 million during the quarter, compared to the consensus estimate of $55.37 million. Research analysts forecast that uniQure will post -2.51 EPS for the current fiscal year.

About uniQure

(Get Rating)

uniQure NV engages in the discovery, development, and commercialization of innovative gene therapies. Its discoveries intend to treat hemophilia, Huntington’s disease, glybera, and cardiovascular problems. The company was founded by Sander J. van Deventer in 1998 and is headquartered in Amsterdam, the Netherlands.